These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 29532242

  • 1. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis?
    Gauthé M, Testart Dardel N, Ruiz Santiago F, Ohnona J, Nataf V, Montravers F, Talbot JN.
    Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
    [Abstract] [Full Text] [Related]

  • 2. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT.
    Yadav D, Ballal S, Yadav MP, Tripathi M, Roesch F, Bal C.
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
    Gaertner FC, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh RA, Sinnes JP, Rösch F, Essler M.
    Nucl Med Biol; 2019 Apr; 76-77():1-9. PubMed ID: 31520872
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 6. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 7. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [Abstract] [Full Text] [Related]

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 11. Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort.
    Yoo J, Kim SH, Jeon SK, Bae JS, Han JK.
    Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
    [Abstract] [Full Text] [Related]

  • 12. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT.
    Nogareda Seoane Z, Mallón Araújo MC, Calatayud Cubes A, Barberán Corral C, Domínguez Novoa Y, Cousillas Castiñeira A, Martínez Lago N, de Matías Leralta JM, Pubul Nuñez V.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024 Oct; 43(3):500011. PubMed ID: 38643835
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, Virgolini IJ.
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E.
    Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
    [Abstract] [Full Text] [Related]

  • 15. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
    Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.
    Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L.
    Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Oct; 38(2):94-99. PubMed ID: 30630744
    [Abstract] [Full Text] [Related]

  • 18. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [Abstract] [Full Text] [Related]

  • 19. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [Abstract] [Full Text] [Related]

  • 20. ⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.
    Calissendorff J, Sundin A, Falhammar H.
    Endocrine; 2014 Sep; 47(1):169-76. PubMed ID: 24272595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.